New York, New York Clinical Trials

A listing of New York, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3302 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Weill Cornell Medical College /ID# 162679
 (5.0 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

Weill Cornell Medical College /ID# 220933
 (4.9 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Weill Cornell Medical College /ID# 220866
 (4.9 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
Study in Parkinson Disease of Exercise

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax …

New York University Langone Health
 (6.9 away) Contact site
  • 0 views
  • 04 Jun, 2021
  • +7 other locations
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

antihypertensive drugs
renal angiogram
hypertension
antihypertensive therapy
hypertensive medication
Columbia University Medical Center/NYPH
 (0.2 away) Contact site
  • 877 views
  • 20 Jun, 2021
  • +82 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

cancer
metastatic cancer
primary cancer
FGFR2
Mt. Sinai Hospital
 (3.4 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder carcinoma
metastatic urothelial carcinoma
urothelial carcinoma
bladder cancer
Mount Sinai School of Medicine
 (3.4 away) Contact site
  • 22 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

FGFR1
myeloid neoplasm
lymphoid malignancy
Weill Cornell Medical College
 (5.0 away) Contact site
  • 79 views
  • 14 Dec, 2020
  • +34 other locations
featured
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

malignant solid tumor
solid tumors
advanced solid tumor
solid tumor
Research Center
 (6.2 away) Contact site
  • 448 views
  • 08 Dec, 2020
  • +14 other locations
featured
A PILOT MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE PROPORTION OF RESPONDERS TO P5D502 AND TO PLACEBO USING THE PEBEQ IN SUBJECTS WITH PREMATURE EJACULATION

A PILOT MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE PROPORTION OF RESPONDERS TO P5D502 AND TO PLACEBO USING THE PEBEQ IN SUBJECTS WITH PREMATURE EJACULATION  

Manhattan Medical Research
 (6.9 away) Contact site
  • 272 views
  • 11 Feb, 2019
  • 1 location